Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Cardiovascular diseases in survivors of childhood cancer.

Bansal N, Blanco JG, Sharma UC, Pokharel S, Shisler S, Lipshultz SE.

Cancer Metastasis Rev. 2020 Mar;39(1):55-68. doi: 10.1007/s10555-020-09859-w. Review.

PMID:
32026204
2.

Contribution of DNA methylation to the expression of FCGRT in human liver and myocardium.

Cejas RB, Ferguson DC, Quiñones-Lombraña A, Bard JE, Blanco JG.

Sci Rep. 2019 Jun 17;9(1):8674. doi: 10.1038/s41598-019-45203-1.

3.

Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.

Quiñones-Lombraña A, Blanco JG.

Exp Mol Pathol. 2019 Oct;110:104268. doi: 10.1016/j.yexmp.2019.104268. Epub 2019 Jun 12.

PMID:
31201803
4.

Insights into the transcriptional regulation of the anthracycline reductase AKR7A2 in human cardiomyocytes.

Quiñones-Lombraña A, Intini A, Blanco JG.

Toxicol Lett. 2019 Jun 1;307:11-16. doi: 10.1016/j.toxlet.2019.02.015. Epub 2019 Feb 25.

PMID:
30817976
5.

Analysis of outpatient HER2 testing in New York state using the statewide planning and research cooperative system.

Hefti E, Jacobs DM, Rana K, Blanco JG.

Pharmacogenomics. 2018 Dec;19(18):1395-1401. doi: 10.2217/pgs-2018-0120. Epub 2018 Nov 6.

PMID:
30398082
6.

CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Quiñones-Lombraña A, Li N, Del Solar V, Atilla-Gokcumen GE, Blanco JG.

Biopharm Drug Dispos. 2018 Jun;39(6):315-318. doi: 10.1002/bdd.2135.

7.

Correction to: Pluripotent Stem Cell-Derived Human Tissue: Platforms to Evaluate Drug Metabolism and Safety.

Meseguer-Ripolles J, Khetani SR, Blanco JG, Iredale M, Hay DC.

AAPS J. 2018 Feb 12;20(2):30. doi: 10.1208/s12248-018-0191-z.

PMID:
29435689
8.

Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181.

Ferguson DC, Blanco JG.

Pharm Res. 2018 Jan 4;35(1):15. doi: 10.1007/s11095-017-2294-0.

9.

Pluripotent Stem Cell-Derived Human Tissue: Platforms to Evaluate Drug Metabolism and Safety.

Meseguer-Ripolles J, Khetani SR, Blanco JG, Iredale M, Hay DC.

AAPS J. 2017 Dec 21;20(1):20. doi: 10.1208/s12248-017-0171-8. Review. Erratum in: AAPS J. 2018 Feb 12;20(2):30.

10.

Investigation of the role of DNA methylation in the expression of ERBB2 in human myocardium.

Quiñones-Lombraña A, Blair RH, Blanco JG.

Gene. 2017 Sep 10;628:286-294. doi: 10.1016/j.gene.2017.07.058. Epub 2017 Jul 21.

11.

Mitochondrial DNA heteroplasmy in cardiac tissue from individuals with and without coronary artery disease.

Hefti E, Blanco JG.

Mitochondrial DNA A DNA Mapp Seq Anal. 2018 May;29(4):587-593. doi: 10.1080/24701394.2017.1325480. Epub 2017 May 19.

12.

Pharmacotherapeutic Considerations for Individuals with Down Syndrome.

Hefti E, Blanco JG.

Pharmacotherapy. 2017 Feb;37(2):214-220. doi: 10.1002/phar.1880. Epub 2017 Jan 13. Review.

13.

The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.

Antillón FG, Blanco JG, Valverde PD, Castellanos M, Garrido CP, Girón V, Letona TR, Osorio EJ, Borrayo DA, Mack RA, Melgar MA, Lorenzana R, Ribeiro RC, Metzger M, Conter V, Rossi E, Valsecchi MG.

Cancer. 2017 Feb 1;123(3):436-448. doi: 10.1002/cncr.30257. Epub 2016 Sep 28.

14.

Analysis of Heteroplasmic Variants in the Cardiac Mitochondrial Genome of Individuals with Down Syndrome.

Hefti E, Bard J, Blanco JG.

Hum Mutat. 2017 Jan;38(1):48-54. doi: 10.1002/humu.23071. Epub 2016 Sep 26.

15.

Transcriptional regulation of the canine carbonyl reductase 1 gene (cbr1) by the specificity protein 1 (Sp1).

Quiñones-Lombraña A, Cheng Q, Ferguson DC, Blanco JG.

Gene. 2016 Oct 30;592(1):209-214. doi: 10.1016/j.gene.2016.08.005. Epub 2016 Aug 6.

16.

Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.

Hoefer CC, Blair RH, Blanco JG.

J Pharm Sci. 2016 Jun;105(6):2005-2008. doi: 10.1016/j.xphs.2016.03.013. Epub 2016 Apr 23.

17.

Documenting Pharmacogenomic Testing with CPT Codes.

Hefti E, Blanco JG.

J AHIMA. 2016 Jan;87(1):56-9. No abstract available.

18.

Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.

Hefti E, Blanco JG.

J Pediatr Hematol Oncol. 2016 May;38(4):283-7. doi: 10.1097/MPH.0000000000000540. Review.

19.

CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study.

Wang X, Sun CL, Quiñones-Lombraña A, Singh P, Landier W, Hageman L, Mather M, Rotter JI, Taylor KD, Chen YD, Armenian SH, Winick N, Ginsberg JP, Neglia JP, Oeffinger KC, Castellino SM, Dreyer ZE, Hudson MM, Robison LL, Blanco JG, Bhatia S.

J Clin Oncol. 2016 Mar 10;34(8):863-70. doi: 10.1200/JCO.2015.63.4550. Epub 2016 Jan 25.

20.

Role of DNA Methylation on the Expression of the Anthracycline Metabolizing Enzyme AKR7A2 in Human Heart.

Hoefer CC, Quiñones-Lombraña A, Blair RH, Blanco JG.

Cardiovasc Toxicol. 2016 Apr;16(2):182-92. doi: 10.1007/s12012-015-9327-x.

21.

Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.

Ferguson DC, Cheng Q, Blanco JG.

Drug Metab Dispos. 2015 Jul;43(7):922-7. doi: 10.1124/dmd.115.064295. Epub 2015 Apr 27.

22.

Chromosome 21-derived hsa-miR-155-5p regulates mitochondrial biogenesis by targeting Mitochondrial Transcription Factor A (TFAM).

Quiñones-Lombraña A, Blanco JG.

Biochim Biophys Acta. 2015 Jul;1852(7):1420-7. doi: 10.1016/j.bbadis.2015.04.004. Epub 2015 Apr 11.

23.

Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review.

Hefti E, Blanco JG.

Cardiovasc Toxicol. 2016 Jan;16(1):5-13. doi: 10.1007/s12012-015-9307-1. Review.

24.

Analysis of mtDNA, miR-155 and BACH1 expression in hearts from donors with and without Down syndrome.

Hefti E, Quiñones-Lombraña A, Redzematovic A, Hui J, Blanco JG.

Mitochondrial DNA A DNA Mapp Seq Anal. 2016;27(2):896-903. doi: 10.3109/19401736.2014.926477. Epub 2014 Jun 18.

25.

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.

Quiñones-Lombraña A, Ferguson D, Hageman Blair R, Kalabus JL, Redzematovic A, Blanco JG.

Pharm Res. 2014 Jul;31(7):1644-55. doi: 10.1007/s11095-013-1267-1. Epub 2014 Feb 22.

26.

Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.

Wang X, Liu W, Sun CL, Armenian SH, Hakonarson H, Hageman L, Ding Y, Landier W, Blanco JG, Chen L, Quiñones A, Ferguson D, Winick N, Ginsberg JP, Keller F, Neglia JP, Desai S, Sklar CA, Castellino SM, Cherrick I, Dreyer ZE, Hudson MM, Robison LL, Yasui Y, Relling MV, Bhatia S.

J Clin Oncol. 2014 Mar 1;32(7):647-53. doi: 10.1200/JCO.2013.50.3557. Epub 2014 Jan 27.

27.

MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024.

Kalabus JL, Cheng Q, Blanco JG.

PLoS One. 2012;7(11):e48622. doi: 10.1371/journal.pone.0048622. Epub 2012 Nov 1.

28.

DNA sequence variants in the carbonyl reductase 1 (cbr1) gene in seven breeds of Canis lupus familiaris.

Cheng Q, Sanborn C, Ferguson D, Blanco JG.

Genet Mol Res. 2012 Apr 27;11(2):1109-16. doi: 10.4238/2012.April.27.10.

29.

Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene.

Kalabus JL, Cheng Q, Jamil RG, Schuetz EG, Blanco JG.

Toxicol Lett. 2012 Jun 20;211(3):266-73. doi: 10.1016/j.toxlet.2012.04.006. Epub 2012 Apr 15.

30.

Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S.

J Clin Oncol. 2012 May 1;30(13):1415-21. doi: 10.1200/JCO.2011.34.8987. Epub 2011 Nov 28.

31.

A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2.

Cheng Q, Kalabus JL, Zhang J, Blanco JG.

Biochem Pharmacol. 2012 Jan 1;83(1):139-48. doi: 10.1016/j.bcp.2011.09.027. Epub 2011 Oct 5.

32.

Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia.

Hampras SS, Sucheston L, Weiss J, Baer MR, Zirpoli G, Singh PK, Wetzler M, Chennamaneni R, Blanco JG, Ford L, Moysich KB.

Int J Mol Epidemiol Genet. 2010;1(3):201-7. Epub 2010 May 20.

33.

Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.

Kalabus JL, Sanborn CC, Jamil RG, Cheng Q, Blanco JG.

Drug Metab Dispos. 2010 Dec;38(12):2096-9. doi: 10.1124/dmd.110.035550. Epub 2010 Aug 20.

34.

A rapid, reproducible, on-the-fly orthogonal array optimization method for targeted protein quantification by LC/MS and its application for accurate and sensitive quantification of carbonyl reductases in human liver.

Cao J, Gonzalez-Covarrubias V, Straubinger RM, Wang H, Duan X, Yu H, Qu J, Blanco JG.

Anal Chem. 2010 Apr 1;82(7):2680-9. doi: 10.1021/ac902314m. Erratum in: Anal Chem. 2010 Sep 15;82(18):7861. Covarrubias, Vanessa M [corrected to Gonzalez-Covarrubias., Vanessa].

35.

Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB.

Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11.

36.

Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.

Zhang J, Blanco JG.

Pharm Res. 2009 Sep;26(9):2209-15. doi: 10.1007/s11095-009-9936-9. Epub 2009 Jul 10.

37.

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.

Gonzalez-Covarrubias V, Zhang J, Kalabus JL, Relling MV, Blanco JG.

Drug Metab Dispos. 2009 Feb;37(2):400-7. doi: 10.1124/dmd.108.024547. Epub 2008 Nov 20.

38.

Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.

Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S.

Cancer. 2008 Jun 15;112(12):2789-95. doi: 10.1002/cncr.23534.

39.

Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER).

Gonzalez-Covarrubias V, Kalabus JL, Blanco JG.

Pharm Res. 2008 Jul;25(7):1730-4. doi: 10.1007/s11095-008-9592-5. Epub 2008 May 1.

40.

Sensitization to serum albumins in children allergic to cow's milk and epithelia.

Vicente-Serrano J, Caballero ML, Rodríguez-Pérez R, Carretero P, Pérez R, Blanco JG, Juste S, Moneo I.

Pediatr Allergy Immunol. 2007 Sep;18(6):503-7.

PMID:
17680908
41.

Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon receptor.

Lakhman SS, Chen X, Gonzalez-Covarrubias V, Schuetz EG, Blanco JG.

Mol Pharmacol. 2007 Sep;72(3):734-43. Epub 2007 Jun 14.

PMID:
17569794
42.

Concordance of pharmacogenetic polymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia.

Weiss JR, Baer MR, Ambrosone CB, Blanco JG, Hutson A, Ford LA, Moysich KB.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1038-41.

43.

A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.

Gonzalez-Covarrubias V, Ghosh D, Lakhman SS, Pendyala L, Blanco JG.

Drug Metab Dispos. 2007 Jun;35(6):973-80. Epub 2007 Mar 7.

44.

The role of genetic variability in drug metabolism pathways in breast cancer prognosis.

Choi JY, Nowell SA, Blanco JG, Ambrosone CB.

Pharmacogenomics. 2006 Jun;7(4):613-24. Review.

PMID:
16753008
45.

Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites.

Covarrubias VG, Lakhman SS, Forrest A, Relling MV, Blanco JG.

Toxicol Lett. 2006 Jul 14;164(3):249-58. Epub 2006 Feb 14.

46.

Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).

Lakhman SS, Ghosh D, Blanco JG.

Drug Metab Dispos. 2005 Feb;33(2):254-7. Epub 2004 Nov 10.

PMID:
15537833
47.

PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.

Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Raimondi SC, Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Lim R, Lim HL, Ong AB, Lee HS, Kuehl P, Zhang J, Lin Y, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS.

Pharmacol Rev. 2004 Jun;56(2):159. No abstract available.

PMID:
15169924
48.

Etoposide induces chimeric Mll gene fusions.

Blanco JG, Edick MJ, Relling MV.

FASEB J. 2004 Jan;18(1):173-5. Epub 2003 Nov 20.

PMID:
14630694
49.

Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.

Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, Rivera GK, Kun LE, Evans WE, Pui CH.

Blood. 2003 May 15;101(10):3862-7. Epub 2003 Jan 16.

PMID:
12531808
50.

Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.

Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Pui CH, Raimondi SC, Relling MV.

Pharmacogenetics. 2002 Nov;12(8):605-11.

PMID:
12439220

Supplemental Content

Loading ...
Support Center